HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy.

AbstractA 42-year-old woman with widespread recalcitrant epidermolysis bullosa acquisita (EBA) responded well to colchicine monotherapy after attempts to control her disease with other modalities failed. These included dapsone, tetracycline, prednisolone, and combination of cyclophosphamide/azathioprine with dexamethasone 'pulse therapy'. The useful role of colchicine in controlling some difficult cases of EBA, a therapeutically problematic condition, is stressed.
AuthorsKomal Pahuja Arora, Bharti Sachdeva, Navjeevan Singh, Sambit Nath Bhattacharya (Affiliation: Department of Dermatology & STD, UCMS & GTB Hospital, Dilshad Garden, Delhi-110095, India.)
JournalThe Journal of dermatology (J Dermatol) Vol. 32 Issue 2 Pg. 114-9 (Feb 2005) ISSN: 0385-2407 [Print] Japan
PMID15906541 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Gout Suppressants
  • Colchicine
Topics
  • Adult
  • Colchicine (therapeutic use)
  • Diagnosis, Differential
  • Epidermolysis Bullosa Acquisita (diagnosis, drug therapy, pathology)
  • Female
  • Gout Suppressants (therapeutic use)
  • Humans
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD